📢 PDC*lung01 Phase I/II results now published in ESMO Open! https://t.co/z4Dr5YMKYl of the Phase I/II clinical study evaluating the therapeutic cancer vaccine PDC*lung01 in patients with non-small cell lung cancer in ESMO Open – the journal of the @myESMO

📢 @pdc_line at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 📷 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1

-> Don’t miss this article

In this interview, Eric Halioua reflects on the start, success and momentum of PDC*line Pharma, a clinical-stage biotechnology company developing allogeneic cellular immunotherapies for cancer. He also shares three top tips for start-up companies on their investment and funding

📢 @pdc_line at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 🧬 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1

@pdc_line is excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025! @EricHalioua , will be attending the event next week in Bruges, Belgium 📅 Learn more: https://t.co/ErDRo5OCXN 📍 Organized by Informa Connect We look forward to seeing you in Bruges!

Excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025 next week in Bruges, Belgium! This year’s theme — “Can European biotech rise to the complexity of the moment?” — couldn’t be more timely. 📅 Learn more: https://t.co/gdu4xM7Xdk

@pdc_line is excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025! @EricHalioua , will be attending the event next week in Bruges, Belgium 📅 Learn more: https://t.co/ErDRo5OCXN 📍 Organized by Informa Connect We look forward to seeing you in Bruges!

👉 New Video following poster presentation at the European Lung Cancer Congress 2025 #ELCC2025 We are pleased to share a video presentation by Prof. Dr. Johan Vansteenkiste, the principal investigator of our clinical trial https://t.co/7AZmEIDi9W

🤝 Clap de fin pour le Festival #Imagésanté ! Toute l’équipe de @pdc_line Pharma est ravie d’avoir une nouvelle fois soutenu cette belle initiative! 📺 Si vous avez manqué cette table ronde, vous pouvez la (re)voir ici 👉 https://t.co/CLRkUtNRv3

🤝 Clap de fin pour le Festival #Imagésanté ! Toute l’équipe de @pdc_line Pharma est ravie d’avoir une nouvelle fois soutenu cette belle initiative! 📺 Si vous avez manqué cette table ronde, vous pouvez la (re)voir ici 👉 https://t.co/2LoEg37iO4

@pdc_line Unveils New Clinical Results with PDC*lung01 at the #ELCC2025 . Poster Title: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDClung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study

Exciting news! Our abstract has been accepted for a poster presentation at the European Lung Cancer Congress (ELCC) 2025. We’re proud to share new data from our ongoing clinical development program with PDC*lung01, our therapeutic cancer vaccine NSCLC. https://t.co/GZs0yeqT0P

Tomorrow’s the day! We’re excited to share that our CEO is speaking at Advanced Therapies UK 2025, where industry leaders will gather for 2 days of insightful discussions, networking, and innovation. There’s still time to join us in London! https://t.co/sE2I7EXtnv #adtherapies

I’m thrilled to be attending the J.P. Morgan Conference in San Francisco from Sunday to Wednesday evening. If you’re attending as well and would like to connect, feel free to reach out or meet me at the conference. Looking forward to dynamic discussions in this hub of innovation!

We are thrilled to be hosting an Executive Roundtable at @WuXi_AppTec #WuXiGlobalForum during #JPM2025! I’m excited to discuss about opportunities of innovative cancer vaccines ! Learn more about the event here: https://t.co/FGdRNR0TFw

La société liégeoise PDC*line Pharma a enregistré de bons résultats cliniques en phase I/II avec son vaccin thérapeutique contre le cancer du poumon. Elle va lever des fonds pour passer à l'étape suivante. @BioWin_asbl @Noshaq_be @biobe_essenscia

[ALA Client News] @pdc_line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024 👉 https://t.co/tC5iNaVyBk #cancervaccine @myESMO #ESMOImmuno24 @EricHalioua

#revuedepresse 💉Des résultats cliniques encourageants pour la biotech liégeoise @pdc_line pour son vaccin thérapeutique contre le cancer du poumon Prochaines étapes : levée de fonds et phase IIB en 2026 #Santé #innovation #wallonie 🗞️@lecho :

https://t.co/hN6FcAHk1X